ArticleBreast cancer (Tokyo, Japan)2026
Exploring a specialized lactylation pattern to predict the prognosis and sensitivity of immunotherapy in breast cancer via machine learning.
Article in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundWith the global incidence of breast cancer steadily increasing, there is a critical need to explore novel molecular mechanisms that drive tumor progression and affect therapeutic response. Lactylation, a recently discovered post-translational modification, has been implicated in various aspects of tumor biology; however, its specific role in breast cancer (BRCA) remains poorly understood. Understanding the association between lactylation and BRCA may offer new insights into prognosis and precision treatment strategies. This study proposes a new framework for understanding the interplay between lactylation and breast cancer progression, with potential implications for prognostic modeling and immunotherapy guidance.
methodsWe performed a comprehensive integrative analysis using multi-omics data from TCGA-BRCA and three independent GEO cohorts. Breast cancer patients were classified into three distinct clusters based on the expression of lactylation-related genes, each exhibiting unique clinical and molecular profiles. To construct a robust prognostic model, 79 machine learning algorithms were evaluated, and the random survival forest (RSF) method was selected as the optimal approach. PGK1 was identified as the most critical predictive gene in the model.
resultsThe RSF-based risk score demonstrated strong prognostic power and was significantly associated with immune cell infiltration and response to immunotherapy in BRCA patients. Functional validation experiments further confirmed that PGK1 knockdown (shPGK1) markedly suppressed breast cancer cell proliferation and migration in vitro.
conclusionsWe developed a novel lactylation-related prognostic model that effectively predicts immunotherapy outcomes in breast cancer and highlights the central role of PGK1 in modulating tumor behavior and immune response.
Indexed as
Identifiers
41637004What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.